Rigel Pharmaceuticals, Inc. (RIGL)
RIGL Stock Price Chart
Explore Rigel Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RIGL price movements and trends.
RIGL Company Profile
Discover essential business fundamentals and corporate details for Rigel Pharmaceuticals, Inc. (RIGL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Nov 2000
Employees
174.00
Website
https://www.rigel.comCEO
Raul R. Rodriguez
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Financial Timeline
Browse a chronological timeline of Rigel Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.14, while revenue estimate is $56.12m.
Earnings released on 5 May 2026
EPS came in at $0.44 falling short of the estimated $0.74 by -40.54%, while revenue for the quarter reached $58.82m , missing expectations by -5.73%.
Earnings released on 3 Mar 2026
EPS came in at $1.14 falling short of the estimated $1.33 by -14.29%, while revenue for the quarter reached $69.80m , beating expectations by +1.60%.
Earnings released on 4 Nov 2025
EPS came in at $1.46 surpassing the estimated $0.93 by +56.99%, while revenue for the quarter reached $69.46m , beating expectations by +1.52%.
Earnings released on 5 Aug 2025
EPS came in at $3.28 surpassing the estimated $1.97 by +66.50%, while revenue for the quarter reached $101.69m , beating expectations by +63.20%.
Earnings released on 6 May 2025
EPS came in at $0.63 surpassing the estimated $0.14 by +350.00%, while revenue for the quarter reached $53.33m , beating expectations by +10.38%.
Earnings released on 4 Mar 2025
EPS came in at $0.80 surpassing the estimated $0.30 by +166.67%, while revenue for the quarter reached $57.60m , beating expectations by +0.01%.
Earnings released on 7 Nov 2024
EPS came in at $0.70 surpassing the estimated $0.06 by +1.07k%, while revenue for the quarter reached $55.31m , beating expectations by +16.63%.
Earnings released on 6 Aug 2024
EPS came in at -$0.06 surpassing the estimated -$0.37 by +83.78%, while revenue for the quarter reached $36.84m , beating expectations by +10.24%.
Stock split effective on 27 Jun 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2024
EPS came in at -$0.50 falling short of the estimated -$0.30 by -66.67%, while revenue for the quarter reached $29.53m , missing expectations by -5.58%.
Earnings released on 5 Mar 2024
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $35.79m , beating expectations by +4.96%.
Earnings released on 7 Nov 2023
EPS came in at -$0.30 surpassing the estimated -$0.70 by +57.14%, while revenue for the quarter reached $28.13m , missing expectations by -5.53%.
Earnings released on 1 Aug 2023
EPS came in at -$0.40 surpassing the estimated -$0.80 by +50.00%, while revenue for the quarter reached $26.89m , beating expectations by +4.61%.
Earnings released on 2 May 2023
EPS came in at -$0.80 surpassing the estimated -$0.90 by +11.11%, while revenue for the quarter reached $26.07m , beating expectations by +8.31%.
Earnings released on 7 Mar 2023
EPS came in at $0.10 surpassing the estimated -$0.70 by +114.29%, while revenue for the quarter reached $51.28m , beating expectations by +40.39%.
Earnings released on 3 Nov 2022
EPS came in at -$1.10 surpassing the estimated -$1.30 by +15.38%, while revenue for the quarter reached $22.41m , missing expectations by -0.88%.
Earnings released on 2 Aug 2022
EPS came in at -$0.80 surpassing the estimated -$1.20 by +33.33%, while revenue for the quarter reached $29.82m , beating expectations by +26.06%.
Earnings released on 3 May 2022
EPS came in at -$1.60 falling short of the estimated -$1.20 by -33.33%, while revenue for the quarter reached $16.74m , missing expectations by -4.79%.
Earnings released on 1 Mar 2022
EPS came in at -$1.30 matching the estimated -$1.30, while revenue for the quarter reached $20.41m , missing expectations by -6.80%.
Earnings released on 2 Nov 2021
EPS came in at -$1.20 falling short of the estimated -$1.00 by -20.00%, while revenue for the quarter reached $21.54m , missing expectations by -8.56%.
Earnings released on 3 Aug 2021
EPS came in at -$0.80 surpassing the estimated -$1.10 by +27.27%, while revenue for the quarter reached $26.27m , beating expectations by +28.94%.
RIGL Stock Performance
Access detailed RIGL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
